Aktienanalyse zu Integra Lifesciences Holdings Corp (IART)IARTIntegra Lifesciences Holdings Corp

Integra LifeSciences Holdings Corporation is a global medical technology company. It manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). CSS consists of technologies and instrumentations used for specialties, such as neurosurgery, neurocritical care, and otolaryngology. CSS neurosurgical business includes a portfolio of brands, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. TT includes Wound Reconstruction and Care business, which sells offerings, such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products. Its products include CUSA Platform, Codman Neurosurgical Accessories, DuraGen Dural Graft Matrix, DuraSeal Dural Sealant System and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Integra Lifesciences Holdings Corp is currently trading at $13.44, which is below the average analyst price target of $15. This suggests that the stock may not be a strong buy at this moment. The RSI is at 34.33, indicating that the stock is in the oversold territory, which could present a buying opportunity if the price stabilizes. However, the company has faced significant challenges, including a negative net income of $4.6 million in Q1 2026 and a forward P/E ratio of 5.9988, which reflects concerns about future earnings growth due to operational disruptions. The main risk is the company's recent downgrade in guidance due to flooding at its Cincinnati facility, which has impacted revenue expectations.

15 analysts cover IART: 9 rate it Buy, 6 Hold and 0 Sell. The average price target is 12.33.